Agreement for production of recombinant C1 Esterase Inhibitor

CEVEC Pharmaceuticals GmbH and CSL Limited have signed an exclusive licensing agreement for the development, manufacture, and commercialization of recombinant C1 Esterase Inhibitor (C1-INH) proteins for HAE and other potential indications using CEVEC’s proprietary CAP®Go technology. 

Under the terms of the agreement, CEVEC grants an exclusive license for the development, manufacture and commercialization of CAP®Go-derived C1-INH proteins to CSL. In addition, CEVEC will provide its expertise in the development and use of CAP®Go cell lines expressing C1-INH, and in optimizing the expression of highly glycosylated and difficult to produce proteins. The licensing agreement was the result of an ongoing collaboration between CSL and CEVEC, which yielded initial data on the significant potential of the CAP®Go technology to enable the development of a differentiated recombinant C1-INH product candidate.

Under the agreement, CSL aims to develop CAP®Go-derived C1-INH proteins with tailored glycosylation, leading to an improved half-life and more convenient application. CEVEC’s proprietary CAP-technology may allow for the industrial manufacture of such a protein given the scalable production process established for CAP®Go cells. 

“The agreement with CSL is a further endorsement of our unique human expression system with the intention to take our CAP®Go technology to the next level of implementation for the production of difficult to express recombinant proteins,” said Dr. Nico Scheer, Chief Business Officer of CEVEC Pharmaceuticals GmbH. “Its outstanding characteristics in terms of authentic and tailor-made glycosylation capabilities, high yield production of complex proteins and scalability, combined with its IP protection and the complete documentation of the CAP® cells make the CAP®Go technology the ideal choice for industrial scale production of glyco-optimized proteins. We are looking forward to supporting CSL with this exciting project.” 

“At CSL, we are patient focused and we are driven by our promise to patients. CEVEC’s CAP®Go technology provides us with the opportunity to develop an innovative and differentiated recombinant and glyco-optimized C1-INH protein for HAE and potential other indications. The potential increase in convenience and quality of life for patients will help us further expand our position in this very important market,” Dr. Andrew Nash Senior Vice President Research, CSL added.
(Source: CEVEC)

2018-05-08T16:17:04+02:00May 8, 2018|HAEi News|